Shinji Itoh

Shinji Itoh

Auto-generated profile, based on publicly available information

Shinji Itoh

Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SHSana Hibino
Sana Hibino
TKTetsuro Kawazoe
Tetsuro Kawazoe
HKHidenori Kasahara
Hidenori Kasahara
SIShinji Itoh
Shinji Itoh
TITakatsugu Ishimoto
Takatsugu Ishimoto
KTKoji Taniguchi
Koji Taniguchi
Inflammation, especially chronic inflammation, plays a pivotal role in tumorigenesis and metastasis through various mechanisms and is now recognized as a hallmark of cancer and an attractive therapeutic target in cancer. In this review, we discuss recent advances in molecular mechanisms of how inflammation promotes tumorigenesis and metastasis and suppresses anti-tumor immunity in various types of solid tumors, including esophageal, gastric, colorectal, liver, and pancreatic cancer as well as hematopoietic malignancies.

26 May 2022 in Cancer Science
Verified
Journal Article
Open access
NINorifumi Iseda
Norifumi Iseda
SIShinji Itoh
Shinji Itoh
KTKatsuya Toshida
Katsuya Toshida
TTTakahiro Tomiyama
Takahiro Tomiyama
AMAkinari Morinaga
Akinari Morinaga
MMMasaki Mori
Masaki Mori
The tyrosine kinase inhibitor lenvatinib is used to treat advanced hepatocellular carcinoma (HCC). Ferroptosis is a type of cell death characterized by the iron‐dependent accumulation of lethal lipid reactive oxygen species (ROS). Nuclear factor erythroid‐derived 2‐like 2 (Nrf2) protects HCC cells against ferroptosis. However, the mechanism of lenvatinib‐induced cytotoxicity and the relationships between lenvatinib resistance and Nrf2 are unclear. Thus, we investigated the relationship between lenvatinib and ferroptosis and clarified the involvement of Nrf2 in lenvatinib‐induced cytotoxicity. Cell viability, lipid ROS levels, and protein expression were measured using Hep3B and HuH7 cells treated with lenvatinib or erastin. We examined these variables after silencing fibroblast growth factor receptor‐4 (FGFR4) or Nrf2 and overexpressing‐Nrf2. We immunohistochemically evaluated FGFR4 expression in recurrent lesions after resection and clarified the relationship between FGFR4 expression and lenvatinib efficacy. Lenvatinib suppressed system Xc− (xCT) and glutathione peroxidase 4 (GPX4) expression. Inhibition of the cystine import activity of xCT and GPX4 resulted in the accumulation of lipid ROS. Silencing‐FGFR4 suppressed xCT and GPX4 expression and increased lipid ROS levels. Nrf2‐silenced HCC cells displayed sensitivity to lenvatinib and high lipid ROS levels. In contrast, Nrf2‐overexpressing HCC cells displayed resistance to lenvatinib and low lipid ROS levels. The efficacy of lenvatinib was significantly lower in recurrent HCC lesions with low‐FGFR4 expression than in those with high‐FGFR4 expression. Patients with FGFR4‐positive HCC displayed significantly longer progression‐free survival than those with FGFR4‐negative HCC. Lenvatinib induced ferroptosis by inhibiting FGFR4. Nrf2 is involved in the sensitivity of HCC to lenvatinib.

15 April 2004 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SIShinji Itoh
Shinji Itoh
TMTakashi Maeda
Takashi Maeda
MSMitsuo Shimada
Mitsuo Shimada
SAShin-Ichi Aishima
Shin-Ichi Aishima
KSKen Shirabe
Ken Shirabe
YMYoshihiko Maehara
Yoshihiko Maehara
Purpose: Although hepatocellular carcinoma (HCC) is the most common cancer of the human liver, the mechanisms that regulate HCC development and progression remain unclear. The aim of this study was to investigate whether focal adhesion kinase (FAK) is involved in the progression of human HCC. Experimental Design: Western blot analysis for FAK was performed on three HCC cell lines. We reviewed 64 consecutive patients who had undergone initial liver resection for HCC without preoperative treatment. Immunohistochemistry analysis for FAK was performed on paraffin-embedded tissues. FAK expression was confirmed by Western blot analysis in several clinical samples. We investigated the correlation between FAK expression and clinical outcome. Results: FAK proteins were detected in all HCC cell lines. Hepatocytes in the normal liver and chronic hepatitis with or without cirrhosis were negative for immunohistochemical staining for FAK expression. Cytoplasmic FAK expression was observed in 18 of 64 patients (28.1%), and this positive staining was correlated with gender (P < 0.05), a lower level of serum albumin (P < 0.05), and portal venous invasion (P < 0.01). Positive staining for FAK was associated with significantly poorer survival (P < 0.05). In multivariate analysis, FAK overexpression was an independent factor in determining the prognosis of patients. Conclusions: These data suggest that FAK plays an important role in promoting tumor progression, especially vascular invasion, in HCC. FAK could play an important role in HCC progression and would be a novel target for HCC therapeutics as well as a prognostic marker.

29 February 2020 in Hepatology
Verified
Journal Article
Closed access
PDF file
SIShinji Itoh
Shinji Itoh
TYTomoharu Yoshizumi
Tomoharu Yoshizumi
KYKyohei Yugawa
Kyohei Yugawa
DIDaisuke Imai
Daisuke Imai
SYShohei Yoshiya
Shohei Yoshiya
MMMasaki Mori
Masaki Mori

10 April 2014 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
SIShinji Itoh
Shinji Itoh
KSKen Shirabe
Ken Shirabe
YMYoshihiro Matsumoto
Yoshihiro Matsumoto
SYShohei Yoshiya
Shohei Yoshiya
JMJun Muto
Jun Muto
YMYoshihiko Maehara
Yoshihiko Maehara

1 February 2021 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
KYKyohei Yugawa
Kyohei Yugawa
Tomoharu YoshizumiTomoharu Yoshizumi
Tomoharu Yoshizumi
YMYohei Mano
Yohei Mano
SIShinji Itoh
Shinji Itoh
NHNoboru Harada
Noboru Harada
MMMasaki Mori
Masaki Mori